This month in PharmaTimes we focus on one of the greatest health threats facing mankind. The newswires have been buzzing with stories about antimicrobial resistance since the publication of the final report of the O’Neill Review at the end of May, with Armageddon-style headlines presaging doom.
A bigger killer than cancer, one person killed every three seconds, 10 million deaths each year from drug-resistant infections by 2050… if nothing is done, of course. Fortunately for the world’s vulnerable population, after a faltering few years, the pharmaceutical industry is now working full-speed ahead on the next generation of antibiotics, an effort spearheaded by small and medium-sized companies.
In Resistance is Futile, we delve into the threat of AMR and profile two SMEs that have taken innovative routes to new antibacterials. We also tackle the issues of AMR in this month’s Patient Files, where twenty-three-year old mum, Emily Morris, speaks candidly about her experiences with a recurrent infection with drug-resistant strain of E coli.
Also in this issue, in Waste Not, Want Not we take a look at efforts to educate patients and healthcare professionals in a bid to cut waste and optimise medicine use in the NHS.
Last but not least, after much research, planning and jubilation we are proud to launch a new-and-improved Pharmatimes.com. In addition to a new-look layout, the updated website bolsters our ongoing and extensive daily news coverage with content from the magazine and web exclusive interviews, industry insight and much much more.
I hope you enjoy this issue.
